The global dementia burden underscores the critical need for innovative treatment approaches. According to the World Health Organization, 55.2 million people worldwide currently live with dementia, with Alzheimer’s disease accounting for approximately 70 percent of cases—roughly 38.9 million individuals. Most significantly, 16.3 million lack access to effective treatment options.
New preclinical research offers potential hope through cannabidiol (CBD), which demonstrated anti-inflammatory effects in mouse models of Alzheimer’s disease. By reducing microglial activation and neuroinflammatory markers, CBD may address a fundamental mechanism underlying cognitive decline.
These findings are particularly significant given the limited therapeutic options available. As the global population ages, the demand for disease-modifying treatments will intensify, making research into emerging compounds like CBD increasingly important for addressing this public health crisis.
Read the full article on GMJ Newsroom.
Was this article helpful?
